<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Pharmacologic therapy is the first line approach to relieve symptoms in obstructive <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>There are no randomized trials to evaluate their effect on prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>Gradient reduction by surgical septal myectomy is associated with excellent prognosis, but not <z:hpo ids='HP_0000001'>all</z:hpo> patients have symptoms severe enough to require surgery; and, guidelines recommend operation only for patients with high gradients and symptoms unresponsive to pharmacologic therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The combination of <z:chebi fb="0" ids="4657">disopyramide</z:chebi> and beta-blockade is effective in reducing resting gradients (though not to the extent of surgery) </plain></SENT>
<SENT sid="4" pm="."><plain>This review examines the question of whether pharmacologic reduction of gradient in asymptomatic patients or those with milder symptoms might decrease HCM-related mortality </plain></SENT>
</text></document>